EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Randomisierte kontrollierte StudieOpen Access

Sirolimus and Cyclosporine With Post-Transplant Cyclophosphamide or Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis in Unrelated Donor Hematopoietic Cell Transplantation

Masumi Ueda Oshima iD, Phuong T Vo iD, Michael Boeckh, Michelle E Bouvier, Paul A Carpenter iD, Marco Mielcarek iD, Effie W Petersdorf iD, Rainer Storb, Ted Gooley, Brenda M Sandmaier iD

Journal of Clinical Oncology · 2025

DOI: 10.1200/jco-25-01238 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Journal of Clinical Oncology, 2025. Verfasst von Masumi Ueda Oshima und 9 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA. Hauptthemen laut MEDLINE: Cyclophosphamide, Cyclosporine, Graft vs Host Disease, Hematologic Neoplasms. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE To determine whether sirolimus (SIR) and cyclosporine (CSP) combined with post-transplantation cyclophosphamide (PTCy), after nonmyeloablative or reduced-intensity conditioning unrelated donor hematopoietic cell transplantation (HCT), would be more effective than SIR, CSP, and mycophenolate mofetil (MMF) in reducing the risk of chronic graft-versus-host disease (cGVHD) without increasing risk of recurrent malignancy. METHODS In a Phase II trial of HLA-matched or mismatched unrelated donor mobilized blood HCT (ClinicalTrials.gov identifier: NCT03246906 ), adults with hematologic malignancies ineligible for myeloablative HCT were randomly assigned 1:1 to GVHD prophylaxis with SIR/CSP/PTCy (50 mg/kg once daily on days +3, +4) or SIR/CSP/MMF. The primary end point was 1-year chronic GVHD-free relapse-free survival (CRFS). RESULTS One hundred forty-five patients were randomly assigned and transplanted. Median follow-up among survivors was 3.0 (range, 0.6-7.0) years. Comparing PTCy-based with non–PTCy-based immunosuppression, estimated 1-year CRFS was 73% (95% CI, 61% to 82%) versus 48% (95% CI, 36% to 59%), translating into a hazard ratio (HR) for CRFS failure of 0.46 (95% CI, 0.26 to 0.79; P = .005) for PTCy. Probabilities of acute GVHD (aGVHD) grades II-IV and III-IV, respectively, were 40% versus 42% and 6% versus 10%. One-year estimates for secondary end points were as follows: moderate-to-severe cGVHD, 3% (95% CI, 1% to 9%) versus 33% (95% CI, 22% to 44%); relapse, 15% versus 15%; progression-free survival, 75% versus 78%; survival, 86% versus 86%; and nonrelapse mortality, 10% versus 7%. The HR of ≥grade 3 infections with PTCy versus non-PTCy was 2.65 (95% CI, 1.41 to 4.97; P = .003). CONCLUSION After HLA-matched or mismatched unrelated donor mobilized blood HCT, replacing MMF with PTCy, when used in combination with SIR and CSP, significantly reduced risk of cGVHD, without increasing risks of aGVHD or relapse. Thus, the combination of PTCy and SIR/CSP may have synergistic cGVHD-protective effects warranting further study.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CyclophosphamideCyclosporineGraft vs Host DiseaseHematologic NeoplasmsHematopoietic Stem Cell TransplantationMycophenolic AcidSirolimusAdolescentAdultAgedFemaleHumansMaleMiddle AgedYoung AdultImmunosuppressive AgentsTransplantation ConditioningUnrelated Donors

Substanzen

CyclophosphamideCyclosporineImmunosuppressive AgentsMycophenolic AcidSirolimus

Autor:innen und Institutionen

  • Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA.
  • Department of Medicine, Division of Hematology and Oncology, University of Washington School of Medicine, Seattle, WA.
  • Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA.
  • Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA.
  • Department of Pediatrics, University of Washington School of Medicine, Seattle, WA.

ORCID-Profile: Masumi Ueda Oshima, Phuong T Vo, Paul A Carpenter, Marco Mielcarek, Effie W Petersdorf, Brenda M Sandmaier

Förderung

  • NCI NIH HHS

Zitieren

APA

Ueda Oshima, M., Vo, P. T., Boeckh, M., Bouvier, M. E., Carpenter, P. A., Mielcarek, M., Petersdorf, E. W., Storb, R., Gooley, T., & Sandmaier, B. M. (2025). Sirolimus and Cyclosporine With Post-Transplant Cyclophosphamide or Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis in Unrelated Donor Hematopoietic Cell Transplantation. Journal of Clinical Oncology. https://doi.org/10.1200/jco-25-01238

Vancouver

Ueda Oshima M, Vo PT, Boeckh M, Bouvier ME, Carpenter PA, Mielcarek M, et al. Sirolimus and Cyclosporine With Post-Transplant Cyclophosphamide or Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis in Unrelated Donor Hematopoietic Cell Transplantation. Journal of Clinical Oncology. 2025. doi:10.1200/jco-25-01238

BibTeX
@article{UedaOshima2025,
  author = {Ueda Oshima, Masumi and Vo, Phuong T and Boeckh, Michael and Bouvier, Michelle E and Carpenter, Paul A and Mielcarek, Marco and Petersdorf, Effie W and Storb, Rainer and Gooley, Ted and Sandmaier, Brenda M},
  title = {Sirolimus and Cyclosporine With Post-Transplant Cyclophosphamide or Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis in Unrelated Donor Hematopoietic Cell Transplantation},
  journal = {Journal of Clinical Oncology},
  year = {2025},
  doi = {10.1200/jco-25-01238}
}
Kostenlos starten →